Dr Konstantinos Tzelepis

The Tzelepis group is focusing on the discovery of novel therapeutic targets and the bench-to-clinic transition of new treatments for aggressive malignancies including acute myeloid leukaemia (AML). Dr Tzelepis’s recent work has led to the development of sophisticated CRISPR screening platforms which formed the basis for his follow-up studies that identified the role of several new cancer vulnerabilities including the RNA methyltransferases METTL3 and METTL1 as well as the splicing kinase SRPK1. Now, his group is investigating how the structures and modifications of the RNA regulate the initiation and maintenance of devastated diseases.